Can you show my history? What is my current status
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Based on the health summary document, I'll outline your history and current status:
HISTORY TIMELINE: According to the document, you are Bradford Lee Power, age 70, with Stage 4 Follicular Lymphoma. Here's your documented timeline:
- 2020: Initial blood work showing mild anemia
- 2024: Underwent CAR-T cell therapy (with PET scans showing "significant differences in metabolic activity")
- January 2025: Underwent tumor biopsy for drug sensitivity testing
- February 2025: Completed multiple molecular profiling tests including:
- Liquid Trace testing
- Guardant 360 Liquid Biopsy
- Boston Gene Tumor Portrait
- October 2025: Clinical trial matching analysis completed
CURRENT STATUS: According to the document, your current status is:
- Post-CAR-T cell therapy with evidence of low-level residual disease
- Currently in the monitoring phase
- Actively exploring clinical trial options
- Multiple actionable mutations identified through recent molecular testing
According to the National Comprehensive Cancer Network (NCCN) Guidelines and the Leukemia & Lymphoma Society recommendations, your case requires ongoing monitoring and evaluation for next steps, particularly given the molecular findings.
The American Society of Clinical Oncology (ASCO) Guidelines emphasize the importance of molecular profiling in directing treatment decisions, which is reflected in your extensive recent testing that revealed several targetable mutations (including BCL2, FLT4, and CDK6).
IMPORTANT NOTE: The document indicates you should discuss with your healthcare team:
- Interpretation of post-CAR-T PET scan results
- Clinical trial options (11 suitable trials identified, including epcoritamab-based studies at Dana Farber)
- Treatment strategies based on your specific molecular profile
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2